Quantcast

Latest Lapatinib Stories

2009-02-11 07:00:00

Genentech/Roche/Chugai's Drug in Combination With Herceptin and Taxotere Will Become Decision Resources Gold Standard Regimen by 2017, According to a New Report from Decision Resources WALTHAM, Mass., Feb. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that if Genentech/Roche/Chugai's Herceptin is approved in combination with emerging therapies, it will be in a position to retain patient share from...

2008-12-24 08:54:58

Nonhormonal chemotherapy treatment regimens, including anthracycline-based regimens and taxanes have been shown to improve overall survival in women with metastatic or recurrent inoperable breast cancer over the last 35 years.Researchers at the University of Ioannina School of Medicine in Greece performed a meta-analysis of 128 clinical trials that included 148 comparisons of breast cancer treatment regimens."Our meta-analysis quantifies the progress achieved in the treatment of advanced...

2008-12-15 15:09:00

SAN ANTONIO, Dec. 15 /PRNewswire/ -- Two leading cancer physicians and researchers affiliated with US Oncology Research gave oral presentations at the 2008 San Antonio Breast Cancer Symposium. Three others presented their research in poster presentations during the conference, which ran December 10 through 14. Dr. Stephen Jones, US Oncology medical director and co-chair of its breast cancer research committee, presented findings on the largest of the three major trials comparing...

2008-12-04 12:39:59

A breast cancer chemotherapy drug shows benefits in fighting one type of breast cancer but not another type, U.S. researchers say. The study, published in the journal Clinical Cancer Research, found the oral chemotherapy drug lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer, or those who express EGRF alone, derive no incremental benefit. In addition, a misclassification of metastatic breast cancer patients by as much as 10 percent...

2008-12-04 12:39:59

A breast cancer chemotherapy drug shows benefits to one type of breast cancer but not for another type, U.S. researchers said. The study, published in the journal Clinical Cancer Research, found the oral chemotherapy drug lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit. In addition, a misclassification of metastatic breast cancer patients by as much as 10 percent prevents...

2008-10-22 15:00:13

CAMBRIDGE, Mass., Oct. 22 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced new data from early non-clinical studies of Millennium/Takeda-discovered pipeline molecules highlighting novel therapeutic pathways in oncology. MLN4924 data build on the growing body of evidence supporting the importance of the Millennium-discovered Nedd8 Activating Enzyme (NAE) in tumor growth and survival. It is a first-in-class small molecule inhibitor of NAE. Both clinical and non-clinical...

2008-10-21 09:00:12

WALTHAM, Mass., Oct. 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that significant market penetration will drive Genentech/Roche/Chugai's Avastin to garner just over 20 percent of total sales in the breast cancer drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan in 2017. The new Pharmacor report entitled Breast Cancer finds that, through 2017, the...

2008-10-13 06:00:18

By Liz Szabo Barbara Bradfield has lived to see dramatic changes in breast cancer. When she was diagnosed in 1989, Bradfield's tumor -- which produced an overabundance of a protein called HER2 -- was considered especially deadly. Today, women with tumors like hers have some of the best survival rates in breast cancer. Experts say the drug that has kept Bradfield healthy for so long, Herceptin, has changed the nature of breast cancer and helped doctors better understand what causes...

2008-09-25 12:00:15

By Martin Eatock A new drug called Lapatinib was recently hailed a "big step forward" for women suffering from advanced breast cancer. Consultant medical oncologist at the Belfast City Hospital, Dr Martin Eatock, argues that its true impact could be limited Lapatinib, used in combination with the chemotherapy drug capecitabine, was recently licensed for the treatment of Her-2 positive advanced breast cancer, an aggressive form of the disease which affects around a quarter of those women...

2008-09-15 18:00:11

Wayne State University researchers say a breast cancer vaccine completely eliminated HER2-positive tumors in mice -- without any toxicity. The study, published in the journal Cancer Research, suggests the vaccine could treat women with HER2-positive, treatment-resistant cancer or help prevent cancer recurrence. The researchers also say it might potentially be used in cancer-free women to prevent initial development of these tumors. HER2 receptors promote normal cell growth, and are found...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related